arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Verastem, Inc.

VSTM
$9.38 ▼ -0.49 (-4.96%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
63 Visible periods
31 Metrics
Absolute Benchmarks
Price Chart
18
Health
Poor
Bearish Absolute basis
auto_awesome

Analytical Summary

On an absolute basis, Verastem, Inc. shows weak fundamentals, weighed down by Return on Invested Capital and FCF Margin (%). These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $939.1M
Dividend Yield —
Revenue Growth 1775.4%
Op. Margin -81.6% ↗
ROIC -67.0% ↘
FCF / Share $-0.44 ↗
Trailing P/E —
Price / Book 17.0x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

63-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$40.08M
↑ +1775.4% —
Net Income Profit after all expenses
$-36.59M
↑ +29.8% —
Operating Margin Operating profit as % of sales
-81.6%
↑ +66.1% —
FCF / Share Free cash flow per share
$-0.44
↑ +17.3% —
Long-Term Debt Long-term obligations
$40.72M
↑ +0.5% —

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Invested CapitalReturn on Invested Capital of -235.0% is weak on an absolute basis (target > 10%)
  • FCF Margin (%)FCF Margin (%) of -444.8% is weak on an absolute basis (target > 10%)
  • Interest CoverageInterest Coverage of -149.50x is weak on an absolute basis (target > 5x)
  • FCF / Net IncomeFCF / Net Income of 0.66x is weak on an absolute basis (target > 1x)

Health Breakdown

Profitability ↓
18
Financial Health ↓
18
Cash Quality ↓
18

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 16 years · 63 quarters